FI104700B - Menetelmä tuotteen valmistamiseksi aktiivisen aineen ihonläpäisevään antoon - Google Patents

Menetelmä tuotteen valmistamiseksi aktiivisen aineen ihonläpäisevään antoon Download PDF

Info

Publication number: FI104700B
Authority: FI; Finland
Prior art keywords: nicotine; agent; reservoir; release; tämä
Prior art date: 1988-06-14

Application number

FI906155A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI906155A0 (fi

Inventor

Robert M Gale

James L Osborne

Melinda Nelson

Su Il Yum

David James Enscore

Patricia S Campbell

Original Assignee

Alza Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-06-14

Filing date

1990-12-13

Publication date

2000-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26901444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI104700(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-12-13 Application filed by Alza Corp filed Critical Alza Corp

1990-12-13 Publication of FI906155A0 publication Critical patent/FI906155A0/fi

2000-03-31 Application granted granted Critical

2000-03-31 Publication of FI104700B publication Critical patent/FI104700B/fi

Links

238000000034 method Methods 0.000 title claims description 15
239000013543 active substance Substances 0.000 title claims description 14
230000008569 process Effects 0.000 title claims description 7
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 39
239000012528 membrane Substances 0.000 claims abstract description 39
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 39
229960002715 nicotine Drugs 0.000 claims abstract description 39
230000000694 effects Effects 0.000 claims abstract description 35
239000007788 liquid Substances 0.000 claims abstract description 4
230000036760 body temperature Effects 0.000 claims abstract 2
239000012790 adhesive layer Substances 0.000 claims description 21
239000002904 solvent Substances 0.000 claims description 16
229920001684 low density polyethylene Polymers 0.000 claims description 15
239000004702 low-density polyethylene Substances 0.000 claims description 14
239000000463 material Substances 0.000 claims description 13
239000003085 diluting agent Substances 0.000 claims description 8
230000007423 decrease Effects 0.000 claims description 7
150000001412 amines Chemical class 0.000 claims description 5
229920001296 polysiloxane Polymers 0.000 claims description 5
230000002411 adverse Effects 0.000 claims description 3
229920001903 high density polyethylene Polymers 0.000 claims description 3
239000004700 high-density polyethylene Substances 0.000 claims description 3
229920002367 Polyisobutene Polymers 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims description 2
239000002480 mineral oil Substances 0.000 claims description 2
235000010446 mineral oil Nutrition 0.000 claims description 2
239000005038 ethylene vinyl acetate Substances 0.000 claims 3
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims 3
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 abstract description 42
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 9
230000001070 adhesive effect Effects 0.000 abstract description 8
239000000853 adhesive Substances 0.000 abstract description 7
WAVYHSURRZBQKO-UHFFFAOYSA-N 1-cyclohexyl-4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butan-1-one Chemical compound C=1C=C(OC)C=CC=1CC(C)N(CC)CCCC(=O)C1CCCCC1 WAVYHSURRZBQKO-UHFFFAOYSA-N 0.000 abstract description 4
ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 abstract description 4
RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 abstract description 4
ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 abstract description 4
230000003247 decreasing effect Effects 0.000 abstract description 4
RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 abstract description 4
229950004117 secoverine Drugs 0.000 abstract description 4
HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 abstract description 3
239000002202 Polyethylene glycol Substances 0.000 abstract description 2
229920001223 polyethylene glycol Polymers 0.000 abstract description 2
GIJXKZJWITVLHI-UHFFFAOYSA-N 3-(diphenylmethyl)oxy-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CC2OC(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-UHFFFAOYSA-N 0.000 abstract 1
239000000126 substance Substances 0.000 description 51
239000003814 drug Substances 0.000 description 24
229940079593 drug Drugs 0.000 description 23
239000010410 layer Substances 0.000 description 22
238000000338 in vitro Methods 0.000 description 17
230000037317 transdermal delivery Effects 0.000 description 13
230000035699 permeability Effects 0.000 description 7
239000000203 mixture Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
238000011067 equilibration Methods 0.000 description 5
239000003623 enhancer Substances 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
238000012377 drug delivery Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
230000035515 penetration Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
231100000245 skin permeability Toxicity 0.000 description 3
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
239000001961 anticonvulsive agent Substances 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000000812 cholinergic antagonist Substances 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
230000007794 irritation Effects 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
229920000728 polyester Polymers 0.000 description 2
231100000430 skin reaction Toxicity 0.000 description 2
230000005586 smoking cessation Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
-1 α-methylethylethyl Chemical group 0.000 description 2
238000012935 Averaging Methods 0.000 description 1
239000004821 Contact adhesive Substances 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
208000027089 Parkinsonian disease Diseases 0.000 description 1
206010034010 Parkinsonism Diseases 0.000 description 1
206010040880 Skin irritation Diseases 0.000 description 1
206010040914 Skin reaction Diseases 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
229940124575 antispasmodic agent Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
229940112822 chewing gum Drugs 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229940124447 delivery agent Drugs 0.000 description 1
230000008451 emotion Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
229920001179 medium density polyethylene Polymers 0.000 description 1
239000004701 medium-density polyethylene Substances 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
229920003052 natural elastomer Polymers 0.000 description 1
229920001194 natural rubber Polymers 0.000 description 1
230000037311 normal skin Effects 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920006254 polymer film Polymers 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
230000036556 skin irritation Effects 0.000 description 1
231100000475 skin irritation Toxicity 0.000 description 1
230000035483 skin reaction Effects 0.000 description 1
229940124535 smoking cessation aid Drugs 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
229920003051 synthetic elastomer Polymers 0.000 description 1
239000005061 synthetic rubber Substances 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
238000012360 testing method Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Dermatology (AREA)
Materials Engineering (AREA)
Hematology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Materials For Medical Uses (AREA)
Steroid Compounds (AREA)

FI906155A 1988-06-14 1990-12-13 Menetelmä tuotteen valmistamiseksi aktiivisen aineen ihonläpäisevään antoon FI104700B (fi)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US20654688A	1988-06-14	1988-06-14
US20654688		1988-06-14
US28428388A	1988-12-14	1988-12-14
US28428388		1988-12-14
PCT/US1989/002561 WO1989012470A1 (fr)	1988-06-14	1989-06-13	Dispositif de distribution transcutanee sous-saturee
US8902561		1989-06-13

Publications (2)

Publication Number	Publication Date
FI906155A0 FI906155A0 (fi)	1990-12-13
FI104700B true FI104700B (fi)	2000-03-31

Family

ID=26901444

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI906155A FI104700B (fi)	1988-06-14	1990-12-13	Menetelmä tuotteen valmistamiseksi aktiivisen aineen ihonläpäisevään antoon

Country Status (14)

Country	Link
EP (1)	EP0427741B1 (fr)
JP (1)	JP2933337B2 (fr)
KR (1)	KR970010059B1 (fr)
AT (1)	ATE161734T1 (fr)
AU (1)	AU630614B2 (fr)
CA (1)	CA1338700C (fr)
DE (1)	DE68928533T2 (fr)
DK (1)	DK175805B1 (fr)
FI (1)	FI104700B (fr)
IE (1)	IE81102B1 (fr)
NO (1)	NO302065B1 (fr)
NZ (1)	NZ229515A (fr)
PT (1)	PT90820B (fr)
WO (1)	WO1989012470A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4943435A (en) *	1987-10-05	1990-07-24	Pharmetrix Corporation	Prolonged activity nicotine patch
AU682813B2 (en) *	1988-06-14	1997-10-23	Alza Corporation	Subsaturated transdermal delivery device
US5152997A (en) *	1990-12-11	1992-10-06	Theratech, Inc.	Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
AU5354994A (en) *	1992-10-15	1994-05-09	Alza Corporation	Delayed onset transdermal delivery device
US6316023B1 (en) *	1998-01-12	2001-11-13	Novartis Ag	TTS containing an antioxidant
US8252319B2 (en)	2004-10-21	2012-08-28	Durect Corporation	Transdermal delivery system for sufentanil
SI1814531T1 (sl)	2004-10-21	2010-10-29	Durect Corp	Transdermalni dostavni sistem

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4379454A (en) *	1981-02-17	1983-04-12	Alza Corporation	Dosage for coadministering drug and percutaneous absorption enhancer
US4704282A (en) *	1984-06-29	1987-11-03	Alza Corporation	Transdermal therapeutic system having improved delivery characteristics
DE3743947A1 (de) *	1987-09-01	1989-03-09	Lohmann Gmbh & Co Kg	Vorrichtung zur gesteuerten abgabe von nicotin, verfahren zu ihrer herstellung sowie ihre verwendung

1989
- 1989-06-12 PT PT90820A patent/PT90820B/pt not_active IP Right Cessation
- 1989-06-13 AU AU38521/89A patent/AU630614B2/en not_active Expired
- 1989-06-13 WO PCT/US1989/002561 patent/WO1989012470A1/fr not_active Ceased
- 1989-06-13 EP EP89907896A patent/EP0427741B1/fr not_active Revoked
- 1989-06-13 CA CA000602649A patent/CA1338700C/fr not_active Expired - Lifetime
- 1989-06-13 DE DE68928533T patent/DE68928533T2/de not_active Revoked
- 1989-06-13 NZ NZ229515A patent/NZ229515A/xx unknown
- 1989-06-13 JP JP1507345A patent/JP2933337B2/ja not_active Expired - Lifetime
- 1989-06-13 KR KR1019900700153A patent/KR970010059B1/ko not_active Expired - Lifetime
- 1989-06-13 AT AT89907896T patent/ATE161734T1/de not_active IP Right Cessation
- 1989-06-13 IE IE189489A patent/IE81102B1/en not_active IP Right Cessation
1990
- 1990-12-06 NO NO905270A patent/NO302065B1/no not_active IP Right Cessation
- 1990-12-13 FI FI906155A patent/FI104700B/fi active IP Right Grant
- 1990-12-14 DK DK199002976A patent/DK175805B1/da not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA1338700C (fr)	1996-11-12
AU3852189A (en)	1990-01-12
IE891894L (en)	1989-12-14
EP0427741A1 (fr)	1991-05-22
IE81102B1 (en)	2000-03-08
NO905270L (no)	1990-12-11
JPH04500322A (ja)	1992-01-23
DK297690D0 (da)	1990-12-14
PT90820A (pt)	1989-12-29
DK297690A (da)	1990-12-14
DK175805B1 (da)	2005-03-07
JP2933337B2 (ja)	1999-08-09
PT90820B (pt)	1995-05-31
DE68928533T2 (de)	1998-07-02
WO1989012470A1 (fr)	1989-12-28
NZ229515A (en)	1993-02-25
NO905270D0 (no)	1990-12-06
KR900701328A (ko)	1990-12-01
KR970010059B1 (ko)	1997-06-20
ATE161734T1 (de)	1998-01-15
AU630614B2 (en)	1992-11-05
EP0427741B1 (fr)	1998-01-07
DE68928533D1 (de)	1998-02-12
NO302065B1 (no)	1998-01-19
FI906155A0 (fi)	1990-12-13

Legal Events

Date	Code	Title	Description
2004-08-31	FG	Patent granted	Owner name: ALZA CORPORATION

Publication	Publication Date	Title
US4908027A (en)	1990-03-13	Subsaturated transdermal therapeutic system having improved release characteristics
US10709669B2 (en)	2020-07-14	Microreservoir system based on polysiloxanes and ambiphilic solvents
US5342623A (en)	1994-08-30	Subsaturated transdermal therapeutic system having improved release characteristics
US4938759A (en)	1990-07-03	Transdermal delivery device having a rate controlling adhesive
US5633008A (en)	1997-05-27	Method of administering nicotine transdermally
FI112171B (fi)	2003-11-14	Menetelmä transdermaalisiin välineisiin soveltuvien polyisobutyleeniliimojen valmistamiseksi
EP1041975B1 (fr)	2002-09-04	Membranes de regulation de debit pour dispositifs d'administration regulee de medicaments
FI79467B (fi)	1989-09-29	Nytt bandage foer administrering av ett laekemedel.
US4698062A (en)	1987-10-06	Medical device for pulsatile transdermal delivery of biologically active agents
US4814173A (en)	1989-03-21	Silicone elastomer transdermal matrix system
FR2567761A1 (fr)	1986-01-24	Dispositif d'apport transdermique pour l'administration de fentanyl
EP0608357A1 (fr)	1994-08-03	Dispositif permettant l'administration transcutanee d'un medicament avec une variation temporelle regulee du flux a travers la peau
KR101942677B1 (ko)	2019-01-25	첩부제
IL147247A (en)	2006-12-31	Microreservoir system based on polysiloxanes and ambiphilic solvents
FI104700B (fi)	2000-03-31	Menetelmä tuotteen valmistamiseksi aktiivisen aineen ihonläpäisevään antoon
KR20020084161A (ko)	2002-11-04	레리세트론 전달용 경피치료시스템
EP1986618A2 (fr)	2008-11-05	Preparation adhesive comprenant du sufentanil et ses procedes d'utilisation
FI95772B (fi)	1995-12-15	Menetelmä aktiivisena aineosana norpseudoefedriiniä sisältävän transdermaalisen terapeuttisen systeemin valmistamiseksi
KR960021015A (ko)	1996-07-18	경피투여용 패취제제
AU682813B2 (en)	1997-10-23	Subsaturated transdermal delivery device
HK1029923B (en)	2003-04-25	Rate controlling membrances for controlled drug delivery devices
HK1069534A1 (en)	2005-05-27	Transdermal therapeutic system (tts) with fentanyl as active ingredient